Reversal of multidrug resistance in murine lymphoma cells by amphiphilic dihydropyridine antioxidant derivative. 2010

Marina Cindric, and Ana Cipak, and Julianna Serly, and Aiva Plotniece, and Morana Jaganjac, and Lidija Mrakovcic, and Tomislava Lovakovic, and Azra Dedic, and Ivo Soldo, and Gunars Duburs, and Neven Zarkovic, and József Molnár
Department of Pathology, School of Medicine, University of Zagreb, Zagreb, Croatia.

BACKGROUND Multidrug resistance, the principal mechanism by which cancer cells develop resistance to chemotherapy drugs, is a major factor in the failure of many forms of chemotherapies. OBJECTIVE The aim of the study was to investigate the effect of K-2-11 on the reversal of multidrug resistance. METHODS The effects of amphiphilic dihydropyridine derivative K-2-11 were tested on MDR1-expressing mouse lymphoma cells and their parental control. The effects of K-2-11 with and without doxorubicin were studied by determination of cell viability, cell proliferation and production of reactive oxygen species. RESULTS K-2-11 caused complete reversal of multidrug resistance of the MDR cells, being much more efficient than the positive control verapamil. Accordingly, the cytotoxic effects of doxorubicin were enhanced by K-2-11, both in the MDR and in parental cell line, while K-2-11 alone did not affect cell viability. K-2-11 also acted as an antioxidant, reducing the cellular generation of reactive oxygen species. CONCLUSIONS Our results indicate the high potential of K-2-11 as a novel antioxidant with potent MDR-blocking ability that should be studied further for development in adjuvant anticancer treatments.

UI MeSH Term Description Entries
D007940 Leukemia L5178 An experimental lymphocytic leukemia of mice. Lymphoma L5178,L5178, Leukemia,L5178, Lymphoma
D004095 Dihydropyridines Pyridine moieties which are partially saturated by the addition of two hydrogen atoms in any position.
D004317 Doxorubicin Antineoplastic antibiotic obtained from Streptomyces peucetius. It is a hydroxy derivative of DAUNORUBICIN. Adriamycin,Adriablastin,Adriablastine,Adriblastin,Adriblastina,Adriblastine,Adrimedac,DOXO-cell,Doxolem,Doxorubicin Hexal,Doxorubicin Hydrochloride,Doxorubicin NC,Doxorubicina Ferrer Farm,Doxorubicina Funk,Doxorubicina Tedec,Doxorubicine Baxter,Doxotec,Farmiblastina,Myocet,Onkodox,Ribodoxo,Rubex,Urokit Doxo-cell,DOXO cell,Hydrochloride, Doxorubicin,Urokit Doxo cell
D004357 Drug Synergism The action of a drug in promoting or enhancing the effectiveness of another drug. Drug Potentiation,Drug Augmentation,Augmentation, Drug,Augmentations, Drug,Drug Augmentations,Drug Potentiations,Drug Synergisms,Potentiation, Drug,Potentiations, Drug,Synergism, Drug,Synergisms, Drug
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000975 Antioxidants Naturally occurring or synthetic substances that inhibit or retard oxidation reactions. They counteract the damaging effects of oxidation in animal tissues. Anti-Oxidant,Antioxidant,Antioxidant Activity,Endogenous Antioxidant,Endogenous Antioxidants,Anti-Oxidant Effect,Anti-Oxidant Effects,Anti-Oxidants,Antioxidant Effect,Antioxidant Effects,Activity, Antioxidant,Anti Oxidant,Anti Oxidant Effect,Anti Oxidant Effects,Anti Oxidants,Antioxidant, Endogenous,Antioxidants, Endogenous
D014162 Transfection The uptake of naked or purified DNA by CELLS, usually meaning the process as it occurs in eukaryotic cells. It is analogous to bacterial transformation (TRANSFORMATION, BACTERIAL) and both are routinely employed in GENE TRANSFER TECHNIQUES. Transfections
D016399 Lymphoma, T-Cell A group of heterogeneous lymphoid tumors representing malignant transformations of T-lymphocytes. T-Cell Lymphoma,Lymphoma, T Cell,Lymphomas, T-Cell,T Cell Lymphoma,T-Cell Lymphomas
D017382 Reactive Oxygen Species Molecules or ions formed by the incomplete one-electron reduction of oxygen. These reactive oxygen intermediates include SINGLET OXYGEN; SUPEROXIDES; PEROXIDES; HYDROXYL RADICAL; and HYPOCHLOROUS ACID. They contribute to the microbicidal activity of PHAGOCYTES, regulation of SIGNAL TRANSDUCTION and GENE EXPRESSION, and the oxidative damage to NUCLEIC ACIDS; PROTEINS; and LIPIDS. Active Oxygen Species,Oxygen Radical,Oxygen Radicals,Pro-Oxidant,Reactive Oxygen Intermediates,Active Oxygen,Oxygen Species, Reactive,Pro-Oxidants,Oxygen, Active,Pro Oxidant,Pro Oxidants,Radical, Oxygen

Related Publications

Marina Cindric, and Ana Cipak, and Julianna Serly, and Aiva Plotniece, and Morana Jaganjac, and Lidija Mrakovcic, and Tomislava Lovakovic, and Azra Dedic, and Ivo Soldo, and Gunars Duburs, and Neven Zarkovic, and József Molnár
January 2003, In vivo (Athens, Greece),
Marina Cindric, and Ana Cipak, and Julianna Serly, and Aiva Plotniece, and Morana Jaganjac, and Lidija Mrakovcic, and Tomislava Lovakovic, and Azra Dedic, and Ivo Soldo, and Gunars Duburs, and Neven Zarkovic, and József Molnár
January 1998, Anticancer research,
Marina Cindric, and Ana Cipak, and Julianna Serly, and Aiva Plotniece, and Morana Jaganjac, and Lidija Mrakovcic, and Tomislava Lovakovic, and Azra Dedic, and Ivo Soldo, and Gunars Duburs, and Neven Zarkovic, and József Molnár
January 1994, Investigational new drugs,
Marina Cindric, and Ana Cipak, and Julianna Serly, and Aiva Plotniece, and Morana Jaganjac, and Lidija Mrakovcic, and Tomislava Lovakovic, and Azra Dedic, and Ivo Soldo, and Gunars Duburs, and Neven Zarkovic, and József Molnár
September 1995, The Journal of urology,
Marina Cindric, and Ana Cipak, and Julianna Serly, and Aiva Plotniece, and Morana Jaganjac, and Lidija Mrakovcic, and Tomislava Lovakovic, and Azra Dedic, and Ivo Soldo, and Gunars Duburs, and Neven Zarkovic, and József Molnár
January 1994, Acta oncologica (Stockholm, Sweden),
Marina Cindric, and Ana Cipak, and Julianna Serly, and Aiva Plotniece, and Morana Jaganjac, and Lidija Mrakovcic, and Tomislava Lovakovic, and Azra Dedic, and Ivo Soldo, and Gunars Duburs, and Neven Zarkovic, and József Molnár
June 2017, Biochemical and biophysical research communications,
Marina Cindric, and Ana Cipak, and Julianna Serly, and Aiva Plotniece, and Morana Jaganjac, and Lidija Mrakovcic, and Tomislava Lovakovic, and Azra Dedic, and Ivo Soldo, and Gunars Duburs, and Neven Zarkovic, and József Molnár
January 1995, Cancer chemotherapy and pharmacology,
Marina Cindric, and Ana Cipak, and Julianna Serly, and Aiva Plotniece, and Morana Jaganjac, and Lidija Mrakovcic, and Tomislava Lovakovic, and Azra Dedic, and Ivo Soldo, and Gunars Duburs, and Neven Zarkovic, and József Molnár
April 2005, Cancer biology & therapy,
Marina Cindric, and Ana Cipak, and Julianna Serly, and Aiva Plotniece, and Morana Jaganjac, and Lidija Mrakovcic, and Tomislava Lovakovic, and Azra Dedic, and Ivo Soldo, and Gunars Duburs, and Neven Zarkovic, and József Molnár
May 1997, Yao xue xue bao = Acta pharmaceutica Sinica,
Marina Cindric, and Ana Cipak, and Julianna Serly, and Aiva Plotniece, and Morana Jaganjac, and Lidija Mrakovcic, and Tomislava Lovakovic, and Azra Dedic, and Ivo Soldo, and Gunars Duburs, and Neven Zarkovic, and József Molnár
January 2016, Asian Pacific journal of cancer prevention : APJCP,
Copied contents to your clipboard!